JP4806190B2 - Ｎ−置換ヒドロモルホン及びそれらの使用 - Google Patents

Ｎ−置換ヒドロモルホン及びそれらの使用

Info

Publication number
JP4806190B2
JP4806190B2 JP2004540164A JP2004540164A JP4806190B2 JP 4806190 B2 JP4806190 B2 JP 4806190B2 JP 2004540164 A JP2004540164 A JP 2004540164A JP 2004540164 A JP2004540164 A JP 2004540164A JP 4806190 B2 JP4806190 B2 JP 4806190B2
Authority
JP
Japan
Prior art keywords
pain
compound
pharmaceutically acceptable
compound according
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004540164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503850A5 (enExample
JP2006503850A (ja
Inventor
カイル，ドナルド，ジェイ．
Original Assignee
ユーロ−セルティーク エス．エイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーロ−セルティーク エス．エイ． filed Critical ユーロ−セルティーク エス．エイ．
Publication of JP2006503850A publication Critical patent/JP2006503850A/ja
Publication of JP2006503850A5 publication Critical patent/JP2006503850A5/ja
Application granted granted Critical
Publication of JP4806190B2 publication Critical patent/JP4806190B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004540164A 2002-09-25 2003-09-24 Ｎ−置換ヒドロモルホン及びそれらの使用 Expired - Fee Related JP4806190B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41325402P 2002-09-25 2002-09-25
US60/413,254 2002-09-25
PCT/US2003/029876 WO2004029059A1 (en) 2002-09-25 2003-09-24 N-substituted hydromorphones and the use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010242645A Division JP2011042681A (ja) 2002-09-25 2010-10-28 Ｎ−置換ヒドロモルホン及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2006503850A JP2006503850A (ja) 2006-02-02
JP2006503850A5 JP2006503850A5 (enExample) 2006-06-29
JP4806190B2 true JP4806190B2 (ja) 2011-11-02

Family

ID=32043224

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004540164A Expired - Fee Related JP4806190B2 (ja) 2002-09-25 2003-09-24 Ｎ−置換ヒドロモルホン及びそれらの使用
JP2010242645A Withdrawn JP2011042681A (ja) 2002-09-25 2010-10-28 Ｎ−置換ヒドロモルホン及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010242645A Withdrawn JP2011042681A (ja) 2002-09-25 2010-10-28 Ｎ−置換ヒドロモルホン及びそれらの使用

Country Status (18)

Country Link
US (1) US6825205B2 (enExample)
EP (2) EP1803724A1 (enExample)
JP (2) JP4806190B2 (enExample)
KR (1) KR20050074462A (enExample)
CN (1) CN100387600C (enExample)
AT (1) ATE360633T1 (enExample)
AU (1) AU2003272642B2 (enExample)
BR (1) BR0314488A (enExample)
CA (1) CA2500118C (enExample)
CY (1) CY1106697T1 (enExample)
DE (1) DE60313478T2 (enExample)
DK (1) DK1543010T3 (enExample)
ES (1) ES2286461T3 (enExample)
MX (1) MXPA05003104A (enExample)
NZ (1) NZ538726A (enExample)
PT (1) PT1543010E (enExample)
WO (1) WO2004029059A1 (enExample)
ZA (1) ZA200502174B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
EP2099764B1 (en) 2006-09-20 2011-07-27 Mallinckrodt Inc. Preparation of substituted morphinan-6-ones and salts and intermediates thereof
US20080234306A1 (en) * 2006-11-22 2008-09-25 Progenics Pharmaceuticals, Inc. N-Oxides of 4,5-Epoxy-Morphinanium Analogs
JP2010510329A (ja) * 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド ７，８−飽和−４，５−エポキシ−モルフィナニウム類似体
JP5875748B2 (ja) * 2007-03-06 2016-03-02 マリンクロッド エルエルシー 第４級ｎ−アルキルモルフィナンアルカロイド塩の調製のための方法
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
WO2009023567A1 (en) * 2007-08-09 2009-02-19 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
CA2702680A1 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009070733A1 (en) * 2007-11-26 2009-06-04 Pharmacofore, Inc. Peripheral phenolic opioid antagonist
EP2896614B1 (en) 2008-05-27 2017-07-12 Mallinckrodt LLC Processes and compounds for the preparation of normorphinans
WO2010028004A2 (en) 2008-09-03 2010-03-11 Mallinckrodt Inc. Substituted berbines and processes for their synthesis
ME02367B (me) 2010-09-21 2016-06-20 Purdue Pharma Lp Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
EP2951160B1 (en) 2013-01-31 2019-04-24 Purdue Pharma LP Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3087057A4 (en) 2013-12-26 2017-06-28 Purdue Pharma LP Ring-contracted morphinans and the use thereof
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
CA2950567A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
CN117567477B (zh) * 2023-11-15 2026-05-26 宜昌人福药业有限责任公司 一种氢吗啡酮和二氢吗啡类药物低分子聚乙二醇化物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023290A1 (en) * 1996-11-25 1998-06-04 Toray Industries, Inc. Antipruritic agent
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3780819T2 (de) * 1987-09-10 1993-01-14 Univ Chicago Quaternaere derivate von noroxymorphon zur behandlung von uebelkeit und erbrechen.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023290A1 (en) * 1996-11-25 1998-06-04 Toray Industries, Inc. Antipruritic agent
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan

Also Published As

Publication number Publication date
EP1543010A1 (en) 2005-06-22
WO2004029059A1 (en) 2004-04-08
PT1543010E (pt) 2007-07-26
DK1543010T3 (da) 2007-09-17
JP2006503850A (ja) 2006-02-02
DE60313478D1 (de) 2007-06-06
JP2011042681A (ja) 2011-03-03
CY1106697T1 (el) 2012-05-23
BR0314488A (pt) 2005-08-02
CA2500118C (en) 2011-04-12
CA2500118A1 (en) 2004-04-08
HK1080456A1 (en) 2006-04-28
US20040067973A1 (en) 2004-04-08
KR20050074462A (ko) 2005-07-18
EP1543010B1 (en) 2007-04-25
NZ538726A (en) 2006-11-30
EP1803724A1 (en) 2007-07-04
US6825205B2 (en) 2004-11-30
DE60313478T2 (de) 2008-01-03
CN1684967A (zh) 2005-10-19
MXPA05003104A (es) 2005-05-27
CN100387600C (zh) 2008-05-14
ATE360633T1 (de) 2007-05-15
ZA200502174B (en) 2006-05-31
ES2286461T3 (es) 2007-12-01
AU2003272642B2 (en) 2009-07-09
AU2003272642A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
JP2011042681A (ja) Ｎ−置換ヒドロモルホン及びそれらの使用
CN105246897B (zh) 阿片样缩酮化合物和其用途
SK61398A3 (en) Use of epinastine in the treatment of pain
US20230404984A1 (en) Formulations of rbp4 inhibitors and methods of use
ME02313B (me) Kristalni konjugat naloksol-polietilen glikol
HU231191B1 (hu) Izotóp tartalmú morfin molekulák
WO2010112865A1 (en) 5-ht receptor modulating compounds
EP1701951B1 (en) Modulators of peripheral 5-ht receptors
US6444649B1 (en) Solid dispersion containing sialic acid derivative
RU2303597C1 (ru) Фармацевтическая композиция, способы ее получения и применения
US20150164835A1 (en) Opioid Salts with Release Properties and Characteristics Useful for Abuse Deterrent Drug Product Formulations
US5929070A (en) Method for treating migraine pain with olanzapine
WO1992014465A1 (de) Verwendung von anellierten tetrahydropyridinessigsäurederivaten für die behandlung neurologischer erkrankungen
HK1080456B (en) N-substituted hydromorphones and the use thereof
EP4482840A2 (en) Naltrexamine derivatives bearing 5-member heterocyclic ring systems as opioid receptor modulators
CN1278684C (zh) 马来酸左旋氨氯地平的制备方法和应用及含其药物组合物
CN116535390B (zh) pH敏感型4-酰胺哌啶类衍生物、药物组合物及其制备方法和应用
CN103450079B (zh) 四氢异喹啉羟基衍生物、其制备方法及其医药用途
CN113166172A (zh) 嘌呤并嘧啶化合物的盐和晶型及其药物用途
CA2541045A1 (en) A descarbonylethoxyloratadine containing pharmaceutical composition
HK1089177B (en) Modulators of peripheral 5-ht receptors
JPWO1994016702A1 (ja) 便通異常の治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110608

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110812

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140819

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees